Compare SVM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | CGEM |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | SVM | CGEM |
|---|---|---|
| Price | $8.68 | $9.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 5.3M | 1.5M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $323,391,000.00 | N/A |
| Revenue This Year | $22.28 | N/A |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | $74.39 | ★ N/A |
| Revenue Growth | ★ 33.99 | N/A |
| 52 Week Low | $2.87 | $5.68 |
| 52 Week High | $8.87 | $13.33 |
| Indicator | SVM | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 44.82 |
| Support Level | $8.04 | $10.01 |
| Resistance Level | $8.87 | $13.10 |
| Average True Range (ATR) | 0.43 | 1.00 |
| MACD | 0.07 | -0.27 |
| Stochastic Oscillator | 87.67 | 3.73 |
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.